ORLANDO -- First-dose reactions to IV ustekinumab (Stelara) may be related to IgE recognition of a carbohydrate allergen in patients, who may be able to tolerate subcutaneous ustekinumab instead ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Ustekinumab is a human interleukin-12 and -23 ... and a 130mg/26mL single-dose vial for intravenous (IV) infusion. According to Sandoz, the product has extended stability and can be re ...

Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

single dose vial for IV infusion. Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection is expected to receive FDA approval in the first half of 2025. About Otulfi Otulfi ...

Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe ...

Ustekinumab is a human monoclonal antibody that ... for injection and a 130 mg/26 mL (5 mg/mL) single dose vial for IV infusion. Otulfi ® in a 45 mg/0.5 mL single-dose vial for subcutaneous ...

YESINTEK will be available in all the same formulations currently provided by Stelara. The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.

This Phase 3 study reaffirms the quality and therapeutic equivalence of YESINTEK compared to reference product, Stelara. The study demonstrated equivalent efficacy, safety, immunogenicity ...

JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U ...